Dermata Reports Topline Findings from Tome Cosmetic Study
Dermata Therapeutics reported topline findings from a 31-participant cosmetic study of its once-weekly Tome Foundational Treatment, including participant assessments of skin appearance and tolerability.
Dermata Therapeutics, Inc. (NASDAQ:DRMA) has reported topline findings from a completed cosmetic study of Tome Foundational Treatment, its once-weekly skin renewal product. The open-label study involved 31 participants who used the treatment once a week for four weeks.
The company said more than 71% of participants were graded as showing an overall improvement in skin appearance after one treatment. Investigators assessed participants at multiple points during the study, including measures related to fine lines, hyperpigmentation, dark spots, smoothness, firmness, radiance and overall appearance.
Participant feedback after four treatments indicated that 93% agreed the product was comparable to a professional in-office procedure. Dermata also reported that 90% agreed they had seen more noticeable results compared with other products.
Dermata reported that the treatment was well tolerated in the study, with no treatment-related adverse events reported.
Tome Foundational Treatment is designed for weekly use and is intended to renew the appearance of skin while improving tone and texture over time. The product uses Bioneedle™, which Dermata describes as a material consisting of 100% freshwater sponge. The company says the sponge is wild harvested and minimally processed into a fine, purified powder.
Dermata develops direct-to-consumer and professional skincare products, drawing on its experience in clinical dermatology and its Bioneedle technology. The company identifies Tome Foundational Treatment as its first commercial product.
The treatment is available as a one-time purchase covering four weekly treatments or through a subscription programme at a discounted price, according to Dermata. The company is headquartered in San Diego, California.
Gerry Proehl, Dermata’s chairman, president and chief executive officer, said the findings provided clinical support for the company’s approach to Tome and its once-weekly format. He also said Dermata was encouraged by the product’s reception following its launch and intended to continue building awareness of the brand.
Dermata cautioned that statements concerning future product launches, market acceptance, commercialisation and the use of study results in marketing activities are subject to risks and uncertainties. The company said actual events or results could differ materially from those statements.
Dermata reported topline findings from an open-label cosmetic study involving 31 participants.
Participants used Tome Foundational Treatment once a week for four weeks.
More than 71% of participants were graded as showing overall skin improvement after one treatment.
Dermata reported that 93% found the treatment comparable to a professional in-office procedure and 90% saw more noticeable results than with other products.
No treatment-related adverse events were reported in the study.
Dermata Therapeutics announced positive topline results from a recently completed cosmetic clinical study evaluating Tome Foundational Treatment, its once-weekly skin renewal treatment. The study assessed changes in skin appearance after four weekly treatments.
Dermata Therapeutics announced the results on October 15, 2026. The announcement covered a recently completed cosmetic clinical study in which participants used Tome Foundational Treatment once a week for four weeks.
The open-label cosmetic study involved 31 participants. Participants were assessed by an investigator at multiple timepoints and completed self-evaluations after four treatments.
The study evaluated endpoints including fine lines, hyperpigmentation, dark spots, smoothness, firmness, radiance and overall appearance. Participants applied Tome Foundational Treatment once a week for four weeks.
Over 71% of study participants were graded as having overall improvements in their skin after one treatment. Dermata Therapeutics reported this as part of the topline findings from the cosmetic study.
Dermata Therapeutics reported that 93% of participants agreed Tome Foundational Treatment was comparable to a professional in-office procedure. The result came from participant evaluations in the cosmetic study.
Dermata Therapeutics reported that 90% of participants agreed they saw more noticeable results with Tome Foundational Treatment compared with other products. This was based on participant feedback in the study.
Dermata Therapeutics reported that Tome Foundational Treatment was well tolerated, with no treatment-related adverse events reported in the study. The study was an open-label evaluation involving 31 participants.
Tome Foundational Treatment is designed to renew the appearance of skin and improve its tone and texture over time. Dermata Therapeutics describes it as a once-weekly treatment intended to be added to an existing skincare routine.
Tome Foundational Treatment is powered by Bioneedle™, which Dermata Therapeutics describes as consisting of 100% freshwater sponge. The company says it wild harvests and minimally processes the sponge into a fine, purified powder.
Tome Foundational Treatment is available for purchase at www.tomeskincare.com. Dermata Therapeutics offers it as a one-time purchase of four weekly treatments or through a subscription programme at a discounted price.
Dermata Therapeutics develops and commercialises direct-to-consumer and professional skincare solutions, using its experience in clinical dermatology and Bioneedle technology. Tome Foundational Treatment is described as the company's first commercial product, with additional innovations planned to follow.
Dermata Therapeutics' shares trade on NASDAQ under the ticker symbol DRMA.
Gerry Proehl, Dermata Therapeutics' Chairman, President and Chief Executive Officer, said the results provide clinical support for the company's approach to skincare and could help demonstrate the potential of a once-weekly treatment. He also said the company was encouraged by the reception to the recent launch, intends to build awareness around the Tome brand and believes the results could provide differentiation for Tome Foundational Treatment; the company cautioned that forward-looking statements involve risks and uncertainties, including product development and commercialisation risks.